Overview
- Third‑quarter revenue reached about $1.105–$1.11 billion, up roughly 13% year over year, with adjusted earnings surpassing expectations.
- Full‑year 2025 guidance increased to $4.27–$4.30 billion in revenue and $12.81–$13.01 in EPS.
- Companion Animal Group grew 14% as reported and 12% organic, while Poultry & Dairy rose 17% reported and 14% organic, led by recurring diagnostics and international growth.
- Gross margin improved to 61.8% and operating margin to 32.1%, supported by reference lab productivity, consumables growth and net price realization.
- Shares rose about 14% intraday as analysts cited reassuring trends yet continued to watch vet visit frequency, pricing dynamics and instrument usage heading into 2026.